Dr. Agarwal's Health Care DuPont analysis

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025


0.69×	0.68×	0.69×
0.84×	0.85×	0.71×
14.5%	14.1%	13.2%
0.55×	0.55×	0.47×
1.86×	1.86×	1.91×
8.6%	8.3%	5.8%
6.8%	6.8%	4.5%

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

AGARWALEYE₹488.70

Dr. Agarwal's Health Care Ltd.

· Pharma & Health

₹ CrorePeersAKUMS ADVENZYMES ALIVUS AARTIPHARM AARTIDRUGS APLLTD CORONA HCGMcap ₹15,482 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
5-Step DuPont — ROE = Tax Burden × Interest Burden × EBIT Margin × Turnover × Leverage
Tax Burden (Net Income/Pretax) ×	0.69	0.68	0.69
Interest Burden (Pretax/EBIT) ×	0.71	0.85	0.84
EBIT Margin %	13.19	14.10	14.52
Asset Turnover ×	0.47	0.55	0.55
Financial Leverage (Assets/Equity) ×	1.91	1.86	1.86
ROE (5-step product, year-end total equity) %	5.78	8.27	8.58
ROE (owners' profit / average owners' equity) %	4.47	6.84	6.84

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.